The HIVMA would prefer to see development of an HIV curriculum, training programs, and a nationally developed certifying exam that would lead to obtaining a Certificate of Added Qualification (CAQ) in HIV Care.
The HIVMA is in advanced discussions with the American Board of Internal Medicine to try to move toward a CAQ, "a daunting amount of work" that, will take years to accomplish and require coordination with other specialties, said Dr.
While the HIVMA argues for a "higher standard" in credentialing HIV specialists, the alternative definition it offered California officials for immediate use entailed less rigorous requirements than those proposed by the AAHIVM.
is in advanced discussions with the American Board of Internal Medicine in an effort to move toward a CAQ, "a daunting amount of work" that will take years to accomplish and require coordination with other specialties, said Dr.
1) See Tables 6 and 7 of 2014 HIVMA
guidelines for other antiretroviral and nonantiretroviral dose adjustments.
43) HIVMA recommends replacing tenofovir with another antiretroviral in people with a confirmed GFR drop greater than 25% to below 60 mL/min.
Table 4 in HIVMA 2014 CKD guidelines offers a concise summary of relative risks for CKD and ESRD conferred by several antiretrovirals, as well as CD4 count, viral load, African descent, female sex, family history of ESRD, age, diabetes, hypertension, and HCV coinfection.
HIVMA experts recommend a thorough workup for people with new-onset kidney disease or newly diagnosed kidney disease (Table 1).
HIVMA 2014 primary care guidelines offer specific advice for blacks and people starting tenofovir:
Both HIVMA and New York State lean toward the Chronic Kidney Disease Epidemiology Consortium (CKD-EPI) equation, which may be more accurate than MDRD for people with HIV.
guidelines call for a cerebrospinal fluid (CSF) exam in several circumstances for HIV-positive people: (41)
CDC and HIVMA
guidelines outline asymptomatic STI screening advice by (1) initial versus subsequent patient visit, (2) gender, and (3) risk (Table 2).